Oncology Vol 28 No 3

Addressing the Challenge of Managing Radiation Use in Medical Imaging: Paradigm Shifts and Strategic Priorities

March 15, 2014

The rise in utilization of medical imaging-especially computed tomography and nuclear medicine-and the issues of perceived, potential, theoretical, and known risks associated with ionizing radiation exposure from imaging have come to the forefront of public and professional awareness, raising concerns and controversies.

Metastatic Relapse After Initial Clinical Stage I Testicular Leydig Cell Tumor

March 15, 2014

A 70-year-old, otherwise healthy man presented to his primary care provider for an annual checkup, at which time a nontender right testicular mass was noted. He denied any symptoms, and his serum alpha-fetoprotein and beta-human chorionic gonadotropin levels were normal.

Meeting the Challenges of Centrally Located Non–Small-Cell Lung Cancer

March 15, 2014

Surgery continues to advance with the availability of new technology, knowledge and skills gained through experience, and collaboration between specialties. Some tumors that were unresectable in years past are now resectable. Other tumors that we currently consider beyond our ability to remove may be conquered in the near future.

Pertuzumab: Increasing the Options

March 15, 2014

At this point, there is expectation that pertuzumab given in the neoadjuvant setting will improve long-term efficacy. We welcome the opportunity to include pertuzumab in the neoadjuvant regimen of patients with HER2-positive breast cancer.

Curbing Potential Radiation-Induced Cancer Risks in Oncologic Imaging: Perspectives From the ‘Image Gently’ and ‘Image Wisely’ Campaigns

March 15, 2014

The purpose of this review is to provide the oncology community with knowledge about the doses used in medical imaging, radiation-induced cancer risks from imaging, and considerations to keep in mind when balancing imaging benefits and risks in pediatric and adult oncologic settings.

Pertuzumab and Its Accelerated Approval: Evolving Treatment Paradigms and New Challenges in the Management of HER2-Positive Breast Cancer

March 15, 2014

This article discusses the development of pertuzumab to date, with a particular focus on the accelerated approval decision. We highlight the need to identify reliable biomarkers of sensitivity and resistance to HER2-targeted therapy, which would make possible the individualization of treatment for patients with HER2-positive breast cancer.